AiLNP

AiRNA

AiTEM

AI驱动`药物递送`和`药物发现`

AI-driven `Drug Delivery` and `Drug Discovery`

<a href="https://oss.metispharmaceuticals.cn/8b7548924bddec55e7690ef05e403bc3.zip" target="_blank">0.zip</a>The 16th CCKS was held in Qinhuangdao on August 26, 2022. CCKS technology evaluation aims to provide a platform and resources for researchers to test knowledge graph and semantic computing technologies, algorithms and systems, bolster the technological development in the field of knowledge graph in China, and promote the integration and coordination of academic achievements and industrial needs. The official announcement disclosed that there are 14 evaluation tasks in this year, encompassing 5 topics in fields of finance, education, military, chemical and etc.; 5,362 teams with nearly 23,000 people participated in the competition. Yang Wenming, Yin Le and Zou Jiali, members of the AI department of METiS Pharmaceuticals, stood out from many other teams and won the evaluation task competition of &quot; Construction and Application of Chemical Elemental Knowledge Graph &quot; with absolute superiority. <div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/3f90a203beea45df01711b79608907a9.jpg" width="682.484px" height="478px" style="width:682.484px;height:478px"/></div><div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/69a2e8b1bd3a2358a3c89630894e55cd.jpg" width="662px" height="440.988px" style="width:662px;height:440.988px"/></div>The main intention of compound property prediction is to find compounds with substandard physical and chemical properties in a short time, so as to reduce risk when candidates entering into clinical trials and improve the drug development success rate. The traditional method of compound property prediction and analysis is usually from experiments, which is costly and time-consuming. A lot of research work has proved that the machine learning technology, especially the depth study on compound property prediction, has huge utilization potential. The drug research and development work are implemented by using sequence (SMILES) or graphs (atomic for the node, chemical bonds for edge) to indicate compounds, and leveraging sequence modeling or graph neural network (GNN) to predict the properties of the compound, so as to improve the efficiency and reduce the research cycle. However, these approaches usually only take the structural information of compound molecules into consideration not the chemical knowledge. Therefore, the organizer constructed the chemical element knowledge graph based on the periodic table of chemical elements, and brought forward the evaluation tasks in regard to the key technologies and applications of the knowledge graph construction.METiS team exploited the following approaches to study the compound molecules: 1) Graph data pre-training technology, the atoms in the molecule are regarded as nodes, chemical bonds as edges, and the chemical molecule as a graph data; 2) Molecular descriptors; 3) Pharmacophore fingerprints. In the pre-training model, 2D information, 3D information and functional groups, etc. of chemical molecules are included comprehensively. Based on the above different approaches, feature vectors are generated to characterize molecules. Secondly, descending the high dimensional sparse vectors (functional group) into lower dimensional dense ones, then integrate these vectors that with various features to generate the ultimate vector characteristic. Lastly, import those vector characteristics for prediction from integrated model, which foretell a precise compound characteristic. Refer to the ensuing disclosed evaluation paper in CCKS2022 for specific methods.“Compound property prediction based on multiple different molecular features and ensemble learning”（website：www.sigkg.cn/ccks2022）<div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/bd02f5344ccec74a51b2b505358b6b8d.png" width="877.491px" height="268px" style="width:877.491px;height:268px"/></div>Schematic Diagram for Molecular CharacterizationThe integration of Pharmacoprint (Gobbi) can improve the final evaluation metrics, but pharmacophore fingerprint is a high-dimensional sparse vector, mainly composed of 0 or 1. For such features with excessive dimensions, AutoEncoder is used to reduce dimension, and label information is also fully used in the process of dimension reduction. The model structure is shown in the following figure. The processed molecular characteristics are spliced and merged, and then import into the model for training.<div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/d51023379ed300462f4b62ebe9ce7e82.png" width="597.993px" height="362px" style="width:597.993px;height:362px"/></div>The winning demonstrated that METiS has made great progress in the field of AI pharmaceutical in terms of the capability of algorithm and model building .<div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/5561f75be6f8f25b1273098cdebd8f2c.png" width="823px" height="204.479px" style="width:823px;height:204.479px"/></div>Now, the team&#x27;s technical solution has been successfully applied to the AiLNP &amp; AiTEM , two core technology platform of METiS. It is an efficient supportive tool for prediction of LNP and solid dispersion system, enabling &quot;AI + pharmaceutical&quot;, shortening the development cycle, improving the R&amp;D efficiency, to achieve more effective innovational delivery material design and more advantageous formulation system. In the future, METiS will endeavor to make great efforts in fundamental research and pharmaceutical R&amp;D in AI pharmaceutical by virtue of its leading scientific research and innovation ability, continue exploring the uncharted area of biology and pharmaceutical benefit from AI technology, to ultimately address the unmet clinical needs. About usMETiS is a biotechnology company that aims to drive optimal therapies across a broad spectrum of diseases by combining drug delivery and drug discovery with artificial intelligence, machine learning, and quantum simulation to address unmet clinical needs. The core team is led by NAE member and a number of MIT scientists, including drug development experts from well-known pharmaceutical companies such as Regeneron, Amgen and Novartis, as well as young talents in artificial intelligence and computing. The participants, Wenming Yang and Jiali Zou, also won the third place in the evaluation task of Medical Named Entity Recognition of CCKS2020.Based on the underlying technology, METiS has built the proprietary core technology platform of AiLNP, AiRNA and AiTEM to predict the physical and chemical and biological characteristics of small molecules and nucleic acid-based drugs in a specific microenvironment. METiS harnessed AI to drive the dry and wet experiment iteration to achieve more effective innovative design, especially in delivery material, nucleic acid sequence and optimization, for a more superior formulation and nucleic acid-based delivery system.AiLNP:AiLNP is an independent developed and self-owned platform, LNP library with a magnitude of tens of thousands of cationic lipids, and it is with independent IP rights of LNP delivery systems. The expression efficiency surpasses the industry standard for more than ten times. At the same time, LNP-based delivery targeting liver, lung, spleen, muscle and organs, tissues, etc., will enable the therapeutics such as, local regeneration, systematic, targeted protein secretion, antibody, enzyme replacement, tumor targeting, and enhance the immune therapy. The delivery and technology success has brought about a number of pipeline cooperation opportunities either from domestic or foreign large pharmaceutical companies.AiRNA: AiRNA uses quantum chemistry and machine learning algorithms, and combines the biological and physicochemical properties of nucleic acids to enhance large-scale design of the full-length mRNA sequence space. It is an mRNA synthesis and purification platform where mRNAs can be rapidly produced, tested in vivo and in vitro, optimized through AI models and experimental iterations, and eventually the mRNA sequences with high stability and high expression efficiency can be effectively designed.AiTEM: AiTEM establishes large-scale design space of formulations. It can generate tens of thousands of formulations per week and obtain the optimal ones within one month. By developing formulations such as solid dispersions, pharmaceutical gels, self-emulsifying granules, and nanoemulsions, or by solubilizing the insoluble compounds, the problems of insoluble and impermeable drugs can be solved.

团队的技术方案已成功运用到剂泰医药的核心技术平台AiLNP和AiTEM中，高效支撑脂质体LNP预测和固分体体系预测两大技术模块。

Now, the team's technical solution has been successfully applied to the AiLNP & AiTEM , two core technology platform of METiS. It is an efficient supportive tool for prediction of LNP and sol

剂泰医药斩获 CCKS 2022 化学知识图谱构建和应用评测冠军

A Recognition from CCKS2022, METiS Snagged First Prize for its Construction and Application of Chemical Elemental Knowledge Graph

<div class="media-wrap image-wrap align-center" style="text-align:center"><img src="https://oss.metispharmaceuticals.cn/921f0d4aa304a252ab53f5bcb8396d7f.gif" width="393" height="168" style="width:393px;height:168px"/></div>With the theme of &quot;Unite Global Startups, Empower Beijing Innovations&quot;, HICOOL 2022 Global Entrepreneurs Summit was held in Beijing from August 26 to 28. HICOOL 2022 Global Entrepreneurship Competition announced the final list of winners, including 7 first prize winners, 21 second prize winners, 42 third prize winners and other 70 prizes. The project named as &quot;AI-driven Drug Delivery and Drug Discovery&quot; initiated by Dr. Lai Caida and Dr. Wang Wenshou, founders of METiS, won the first prize, the highest award among all the competition.<div class="media-wrap image-wrap align-center" style="text-align:center"><img src="https://oss.metispharmaceuticals.cn/ddf26ed85690a359b8ba76daa98ec543.png"/></div>About HICOOL 2022 Global Entrepreneurship CompetitionHICOOL is a one-stop ecological platform for entrepreneurship sponsored by Beijing Overseas Talents Association (BOTA). Competitions, summit, ecosystem and other modes provided supportive approaches to consolidate the work of talent mining, talent introduction, talent services and talent protection, which enables technology-driven entrepreneurship and value-driven innovation. It is a high-profile competition which attracts 91 countries and regions, 5,016 entrepreneurial projects and 6,672 entrepreneurial talents to participate; It covers seven professional industry areas, artificial intelligence/virtual reality/financial technology, medicine and healthcare, new generation of information technology, cutting-edge equipment, new energy/new materials/energy conservation and environmental protection, cultural creativity, agricultural science and technology/food technology. The competition usually invites top investors, well-known panels and top entrepreneurs to provide the whole process of entrepreneurship guidance and ability to accelerate projects. More excitingly, it provides thoughtful &quot;Beijing Services&quot;, such as talent residency, children&#x27;s education service, medical insurance and talent apartment, so as to continuously empower entrepreneurs.<div class="media-wrap image-wrap align-center" style="text-align:center"><img src="https://oss.metispharmaceuticals.cn/84636602b9f894212918764773ca308d.png"/></div><div class="media-wrap image-wrap align-center" style="text-align:center"><img src="https://oss.metispharmaceuticals.cn/10fec7d3f04dfa2109ac312508d44802.jpg" width="635" height="347" style="width:635px;height:347px"/></div>On the evening of June 26, Dr. Lai Caida, Co-founder and CEO of, METiS, attended the HICOOL 2022 Global Entrepreneurship Competition Award Ceremony and delivered an electric speech. He said, &quot;It is a great honor for the team to win the first prize. The gratifying R&amp;D progress of METiS not only benefit from the core technology platform and core team, but also the favorable pharmaceutical environment of Beijing, and the high-quality supportive resources provided by the industrial park and the talent subsidy policies of relevant government authorities. We believe that with the HICOOL Entrepreneurship Competition platform and the outstanding resource integration capability of the organizers, many high-quality entrepreneurial teams domestically or abroad will be in the limelight, and they will fully demonstrate their technological innovation with a burgeoning growth.&quot;On the afternoon of 28th, Dr. Lai was invited to attend the &quot;Global Entrepreneur Day&quot; of HICOOL 2022 Global Entrepreneurs Summit. He gave a ‘flash mob roadshow’ to present the content and highlights of the winning project.The name of the project is &quot;AI-driven Drug Delivery and Drug Discovery&quot;. METiS, as the world&#x27;s first innovational AI-driven drug delivery and drug discovery biotechnology company, on the one hand, is developing small molecule drugs by improving the drug biological availability, stability, forms and new carrier system to overcome the hurdles of small molecule drugs, aiming to design reformulated novel drugs with clinical individual differentiation. On the other hand, it challenges the long-hold mindset from molecular design to drug delivery, an inevitable process of new modality drugs. It deeply set about the new modality drugs process from encoding, DNA, RNA, then to protein, enabling the products to be stably delivered to the target organs to achieve precise targeting and treatment.Now, the company has applied for a number of patents with crucial application value, and deployed a number of small molecule and nucleic acid research and development pipelines, among which the pipeline with faster progress is expected to carry out pivotal clinical trials in 2023. It is worth mentioning that METiS has built the capability of nucleic acid drug development with the integration of mRNA sequence design and LNP delivery system design with its independent intellectual property rights. The expression efficiency of its LNP nucleic acid delivery system is more than ten times higher than the industry gold standard, and it also achieves targeted delivery to liver, lung, spleen, muscle and other organs or tissues. From that, it enables METiS to achieve local regeneration, systemic/targeted protein secretion, antibody, enzyme replacement, tumor targeting, immunoenhancement and other treatments, which has brought a number of pipeline collaboration opportunities from domestic and foreign large pharmaceutical companies.METiS has outshined from many high-quality projects in HICOOL 2022 Global Entrepreneurship Competition with the first prize bagged, which fully demonstrated the high innovation level of the company&#x27;s core technology platform and its wide application and development prospects. We believe that under the drive of HICOOL platform and high-quality resources, METiS will have a further development in terms of cooperate development, R&amp;D innovation, and talent benefits, etc. The enterprise will not fail the recognition from the honorary award. METiS will keep on solving the unmet clinical needs for the patients with more high-quality therapeutics, parlaying the platform benefits from the integration of artificial intelligence, machine learning, quantum simulation and other cutting-edge technologies.

HICOOL 是由北京海外高层次人才协会作为主办方的一站式创业生态平台，参赛报名范围覆盖全球91个国家和地区、5016个创业项目、6672位创业人才。

HICOOL is a one-stop ecological platform for entrepreneurship sponsored by Beijing Overseas Talents Association (BOTA).It is a high-profile competition which attracts 91 countries and regions

剂泰医药项目荣获HICOOL 2022全球创业大赛海外组一等奖

METiS Bagged Oversea Group First Prize in 2022 HICOOL Global Entrepreneurship Competition 

<div class="media-wrap image-wrap"><img class="media-wrap image-wrap" src="https://oss.metispharmaceuticals.cn/c8a8b211cdd79304acc27d0c38afaf33.jpg"/></div>On August 9, 2022, the BSA Future Star Award, which was initiated and jointly hosted by the 2nd China International Vaccine Innovation Summit and Industry Panelists, came to a perfect conclusion. After furious competition, 10 companies entered the final competition and the final winner got unveiled. METiS Pharmaceuticals, is honored to bag the BSA Future Star Award.<div class="media-wrap image-wrap align-left" style="text-align:left"><img size="1" _root="[object Object]" src="https://oss.metispharmaceuticals.cn/af930f7ca824708c1f068060ad3bdad9.jpg"/></div><div class="media-wrap image-wrap"><img class="media-wrap image-wrap" src="https://oss.metispharmaceuticals.cn/f1be90a70ab3e98528488b569f2caadb.jpg"/></div>METiS Representative in Awards PresentationBest Start-Up Awards (BSA) is focusing on vaccine industry since its initiation of the first China International Vaccine Innovation Summit in 2021, it is also knowns as an appraisal competition among those vaccine start-ups in China. BSA is gathering the KOLs, dark horses in vaccine business, and industry leading media together, tracking the business case in vaccine industry with in-depth insights. With the focus on the scientific definition of business model in vaccine area, team, technical direction, investment potential, etc., and with the purpose of establishing the evaluation system for vaccine industry start-ups, BSA is to comprehensively evaluate the innovation capability, business model, team, technical capability and development prospects of Chinese vaccine enterprises.BSA aims to praise the best ‘entrepreneurship and innovation’ paradigms of Chinese vaccine start-ups, so as to foster the transformation of commercial innovation from scientific research achievement, and to provide investment guidance with high reference value for domestic and foreign investors.METiS Pharmaceuticals (METiS), as a biotechnology company, has been persistent in bring best-in-class therapies across a broad spectrum of diseases, by combining drug delivery &amp;discovery with AI, machine learning, and quantum simulation, to ultimately address unmet clinical needs.The integration of AI, quantum simulation and high-throughput experimental platform and other interdisciplinary technologies enables METiS to build the unique AiLNP, AiRNA and AiTEM core technology platforms to predict the physical, chemical and biological characteristics of small molecules and nucleic acid drugs in a specific micro-environment. By virtue of AI iterations from dry and wet experiment, METiS has achieved more effective innovative delivery material design, nucleic acid sequence design and optimization, and has designed more advantageous formulation or nucleic acid-based delivery system.

BSA意在褒扬传播中国疫苗创业企业的最佳“创业创新”模型，从而推动中国疫苗企业商业创新转型，科研成果转化，为国内外投资者提供高参考价值的投资指引。

BSA aims to praise the best ‘entrepreneurship and innovation’ paradigms of Chinese vaccine start-ups, so as to foster the transformation of commercial innovation from scientific research achi

剂泰医药获选BSA未来之星奖项

METiS Pharmaceuticals won the BSA Future Star Award

By looking back 20 years development path, it is a significant testimony that only technology &amp;science innovation can bring a long-term development.In March of this year, ‘Science and Technology Innovation Daily’ and the Institute of Scientific and Technical Information of Shanghai (ISTIS) jointly launched the &quot;2022 Science and Technology Pioneer &quot; list. After more than four months of information collection, data verification and multi-dimensional rating, the list is officially unveiled.A total of 97 pioneering science &amp; technology entrepreneurs divvyed up in four lists, including 30 scientist entrepreneur pioneers, 15 industry driving scientists pioneers, 20 female scientist entrepreneurs pioneers, and 32 pioneering entrepreneur elites.From the outcome of the list, the list is mainly from the new generation of information technology, biomedical, enterprise services, cutting-edge manufacturing and other essential science and technology innovation areas, they are focusing on the forefront of each area, hoping to foster the development of the industry through independent research and development of scientific and technological innovation technology products, explore a new scenario for scientific and technological innovation application.The list is generated based on two aspects: academic aspect and business aspect.From an academic aspect: the basic dimension to judge the scientific research background of scientists based on academic ability, academic level and academic status. Business aspect: basic dimensions to judge leadership, scientific creativity and business ability of scientific innovators. There are different criteria and focus areas of each list from the three.Let’s have a view of the lists:<div class="media-wrap image-wrap"><img src="https://oss.metispharmaceuticals.cn/0f09bba713d6d9fc1205838199ab09ea.png"/></div>For the list of scientist entrepreneur pioneer, we found that 48.9 % are from the next generation of information technology field. In terms of the founders&#x27; background, 84.4% of the list have a PhD degree, 62.2% have overseas study experience, and 73.3% have overseas work experience. In terms of academic achievement, 68.9% of the list have worked or had part-time experience in universities or scientific research institutions (more than 20% of the list are from the Chinese Academy of Sciences), 55.6 % have won national science awards, and 48.9% have accumulated more than 10 years of experience in their fields. In terms of corporate governance structure and team composition, cooperative teams with more than 10 years account for 48.9%, and 62.2% of the core team have a share of more than 10% of the company. Listed member with both features mentioned above accounted for 31.1 %.Scientists &amp;entrepreneurs represented by Jiangxing Intelligence’s Liu Jiangchuan and AISpeech’s Yu Kai, have made great academic achievements. Due to its outstanding number of patent achievements, TGZX has a relatively impressive performance in the scientific research area. From a commercial aspect, of the listed enterprises, round B, round C and round A accounted for 28.9%, 26.7% and 20% of the financing rounds, respectively. Those who have studied the track for more than 10 years accounted for 57.8%.In addition, we were pleasantly surprised to find that there were many outstanding enterprises whose founders had a very deep industrial background, and their commercial value was fully demonstrated because of their rich scientific research background and previous work experience in large enterprises. Their company&#x27;s financing rounds are mostly divvyed up in B and C rounds. Among them, 46.7 percent of such enterprises received investment from first-line industrial capital. It is noteworthy that up to 60% of enterprises have received investment from the national industrial funds. Among them, Holomatic and Hyperview, are under the limelight.<div class="media-wrap image-wrap"><img src="https://oss.metispharmaceuticals.cn/d929ce2b7050615fb0cc6d22d6047453.jpg"/></div>For the pioneering entrepreneur elite list, from the perspective of educational background, 60.6% of the list has overseas study experience, more than 90% of them are graduated from the QS World Top 100 universities. Overall, 46.8% of the founders had a doctorate degree, and 47% of those on the list were trained by leading scientists in their field. Most of the elites are from the new generation of information technology and cutting-edge manufacturing area, accounting for 34.4% and 28.1% respectively. Among those on the list, 37.5% are serial entrepreneurs, 56.3% have work experience in the world&#x27;s top 500 or China&#x27;s top 500, and 46% have commercialized their patent achievements. In terms of the performance of enterprises in the financing market, B-round enterprises account for 34.3%, and 68.8% of the listed enterprises have received investment from Head dual-currency VC.<div class="media-wrap image-wrap"><img src="https://oss.metispharmaceuticals.cn/f6ddd8760057f2e743bed5f70c92cf56.jpg"/></div>For the list of female entrepreneur pioneers, the original purpose of this list is to better explore the contribution of female roles in science and innovation, and on the other hand, to objectively present the business environment of contemporary women entrepreneurship and the true aspirations of female science and innovation pioneers. Of the 20 top female innovators on the list, 12 are founders/cofounders, and 55% have a master&#x27;s degree. Compared with scientists or entrepreneur elites, the academic performance of female science and innovation elites is relatively in common level, but from the perspective of past work experience, 12 of them have worked in the global 500, and 4 of them have D-level work experience. 35% of the financing rounds of the listed companies are Series A. Among them, Beijing Ai Robotics led by Shuaimei, Graviti led by Wu Qiongjing, Qingflow led by Li Tingting and other enterprises show outstanding performance in the capital market.In order to better understand the current situation of women in the field of science entrepreneur, the list also conducted a separate individual survey on a number of female science entrepreneurs. We have learned that in the current core executive team of female entrepreneurs, women can almost ensure that more than 20% of the C-suite are female. However, the small number of women in the research field and the limited proportion of female executives in the industry are also critical features. As a female entrepreneur, &quot;personal life balance&quot; is the most difficult transition process. At the same time, many women also mentioned that they may have encountered repeated verification of their scientific research achievements, unfair treatment of scientific research funds, and discrimination in the process of corporate financing. We also observed that the majority of participants agreed that &quot;entrepreneurship is difficult, gender discrimination is wrong &quot;, and that the pressures and difficulties faced by both men and women, from scientists to entrepreneurs, were similar. Hereby, we call on more women to participate in China&#x27;s science and technology entrepreneurship, and call on the society to treat women entrepreneurs in a more fair manner.Overall, in terms of research experience of years in relevant areas, pioneering scientists show their long-term commitment -- 70.5% of the listed scientists have studied for more than 10 years in specific subject. While the scientific innovation elite, as the new generation of scientific innovation, their research years are evenly divvyed up in 10 years, 5-10 years, 3-5 years. To translate to relevant products or services with their own scientific research achievements, and then develop innovative manufacturing enterprises or innovative service enterprises, is the idea of changing the identity from scientist to entrepreneur. However, the commercialization of individual patents is not so easy. In this ranking list, less than half of the scientific innovators have commercialized their individual patents.Team, VCs and other external factors will help to pave the road for science and technology entrepreneurship. Among the listed entrepreneurs, the cooperation time with the core team is divvyed up around 6-10 years, and the shareholding ratio of the core team members other than the listed ones is more than 10% on average. In terms of financing, the listed companies are in many rounds of A and B financing stage. Among the top well-known investment institutions that have been supported, two-thirds of the members are from Star-Edge Pioneer Alliance.Lastly, in order to further analyze the &quot;leadership&quot; of the participants, we also listed the ‘Five Personality Scale’ in the data collection stage, so that the participants could self-evaluate in five perspectives: openness, responsibility, extraversion, agreeableness and emotional stability. According to the results, most participants choose &quot;openness&quot;, which corresponds to &quot;imaginative, emotional, creative and unconventional&quot;, while &quot;agreeableness&quot; and &quot;extroversion&quot; are the least selected, which reflect the positioning and expectation of scientists entrepreneurs. The scientist entrepreneur pioneers are a group of people who are not hasty but imaginative and creative.The evaluation dimensions and scoring of this list are jointly completed by ‘Science and Technology Daily’, Institute of Scientific and Technical Information of Shanghai (ISTIS) and Star Mining Data. Science and Technology Board Daily reserves the final right to interpret the list.

榜单上榜者主要来自新一代信息技术、生物医疗、企业服务、高端制造等科创核心赛道，他们专注于各赛道前沿领域，希望通过自主研发的科技创新技术产品，推动行业发展，探索科技创新落地的全新场景。

The list is mainly from the new generation of information technology, biomedical, enterprise services, cutting-edge manufacturing and other essential science and technology innovation areas, 

核心技术

业务|Business

管线|Pipeline

剂泰医药斩获 CCKS 2022 化学知识图谱构建和应用评测冠军

剂泰医药项目荣获HICOOL 2022全球创业大赛海外组一等奖

剂泰医药获选BSA未来之星奖项

赖才达博士获选“2022先锋科创家系列”榜单